CorMedix (CRMD) vs Evotec (EVO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
CorMedix (CRMD) has outperformed Evotec (EVO) over the past year, losing 34.4% versus a loss of 58.9%. Over five years, CRMD leads with a +47.1% price change compared with -92.9% for EVO. Evotec is the larger company by market cap ($572.2 million vs $567.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRMD | EVO |
|---|---|---|
| Share price | $7.28 | $1.61 |
| Market cap | $567.43M | $572.18M |
| 1-day change | 0.00% | -1.23% |
| YTD return | -37.40% | -47.73% |
| 1-year return | -34.36% | -58.93% |
| 5-year return | +47.07% | -92.87% |
| P/E ratio (TTM) | 3.55 | — |
| Forward P/E | 20.80 | — |
| EPS (TTM) | $2.05 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.02 | $4.27 |
| 52-week low | $6.13 | $1.50 |
| Distance from 52-week high | -44.09% | -62.30% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +110.58% | +158.39% |
| Average volume | 1.06M | 104.15K |
| Shares outstanding | 77.94M | 355.39M |
| Employees | 191 | 4,461 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRMD has outperformed EVO by 24.6 percentage points over the past year.
About CorMedix
CRMD stock →CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
Healthcare · Biotechnology · 191 employees
About Evotec
EVO stock →Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics.
Healthcare · Drug Manufacturers - Specialty & Generic · 4,461 employees
CRMD vs EVO FAQ
Which is bigger, CorMedix or Evotec?
Evotec (EVO) is larger, with a market capitalization of $572.18M compared with $567.43M for CorMedix (CRMD).
Which stock has performed better over the past year, CRMD or EVO?
CRMD returned -34.36% over the past 12 months, compared with -58.93% for EVO (price return, excluding dividends). Past performance does not predict future results.
Are CorMedix and Evotec in the same industry?
Both are in the Healthcare sector, but in different industries: Biotechnology for CorMedix and Drug Manufacturers - Specialty & Generic for Evotec.